Trial · NCT01012414
Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease
NCT01012414, Phase 3, Terminated, Thomas Jefferson University; results first posted 2013-11-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease. Trials, record NCT01012414. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01012414
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidney Disease
- NCT number
- NCT01012414
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 10 participants, actual
- Lead sponsor
- Thomas Jefferson University
- Conditions
- Coronary Artery Disease, Chronic Kidney Disease, Hypovitaminosis D, Secondary Hyperparathyroidism
- Interventions
- paricalcitol, placebo
- First posted
- 2009-11-13
- Last updated
- 2014-05-20
- Results first posted
- 2013-11-11
- Limitations and caveats
- Early termination secondary to enrollment futility.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in High Sensitivity-C Reactive Protein (Serum) | 1 year | |
| Secondary | Change in Markers of Inflammation Including Interleukin (IL)-1, IL-6, Tumor Necrosis Factor Alpha, Matrix Metalloproteinase (MMP) -9 and Serum Amyloid A | 1 year | |
| Secondary | Effect on Known Coronary Artery Disease Risk Factors Including Lipids and Blood Pressure. | 1 year | |
| Secondary | Effect on Carotid Intima-media Thickening (CIMT) | 1 year |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in High Sensitivity-C Reactive Protein (Serum) | 1 year | Data were not collected when study was stopped prematurely. | ||
| SECONDARY | Change in Markers of Inflammation Including Interleukin (IL)-1, IL-6, Tumor Necrosis Factor Alpha, Matrix Metalloproteinase (MMP) -9 and Serum Amyloid A | 1 year | Data were not collected when study was stopped prematurely. | ||
| SECONDARY | Effect on Known Coronary Artery Disease Risk Factors Including Lipids and Blood Pressure. | 1 year | Data were not collected when study was stopped prematurely. | ||
| SECONDARY | Effect on Carotid Intima-media Thickening (CIMT) | 1 year | Data were not collected when study was stopped prematurely. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | All Participants | 10 | |
| Overall Study | COMPLETED | All Participants | 0 | |
| Overall Study | NOT COMPLETED | All Participants | 10 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Left rotator cuff surgery | Musculoskeletal and connective tissue disorders | All Participants | 1 | 10 | 1 |
| other | bilateral cataract surgery | Surgical and medical procedures | All Participants | 1 | 10 | 1 |
| other | Cramping in left hand | Musculoskeletal and connective tissue disorders | All Participants | 1 | 10 | 1 |
| other | Muscles cramp, fever, hypotension, | General disorders | All Participants | 1 | 10 | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | All Participants | ||
| Total, other adverse events | All Participants | 4 | 10 |
| Total, serious adverse events | All Participants | 0 | 10 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01012414
GET https://conductscience.org/api/trials/v1/NCT01012414/registered